In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

Researchers from the Wilmer Eye Institute, Johns Hopkins Medicine Center for Nanomedicine - which designs nanotechnology-based platforms for clinical translation across specialties - developed a ...

Explore LENN nanoparticles, a groundbreaking technology for delivering mRNA therapies to bladder cancer cells with enhanced ...

In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...

Researchers at the Icahn School of Medicine at Mount Sinai say they have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a ...

In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...

YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) ...

– GEMORNA is world’s first generative AI platform purpose-built for mRNA design and optimization, demonstrating state-of-the-art performance across diverse mRNA therapeutic applications – – GEMORNA ...